Key result
Non-invasive cardiac biosignals, most commonly 24-hour ECG SDNN, independently predict adverse events in chronic HF.
Why the study?
The study was conducted to identify parameters of non-invasively recorded cardiac biosignals associated with adverse events in patients with chronic heart failure.
Are non-invasively recorded cardiac biosignals associated with the development of adverse events in patients with chronic heart failure?
Systematic Review (n=42)
Are non-invasively recorded cardiac biosignals associated with the development of adverse events in patients with chronic heart failure?
Non-invasive biosignals, particularly SDNN from 24-hour ECG, are useful predictors of adverse events in chronic heart failure, with predictive value enhanced when combined with clinical parameters.
Supports biosignal monitoring for HF risk stratification; extends evidence with RCT validation of guided therapy.
Objective. To identify parameters of non-invasively recorded cardiac biosignals associated with the development of adverse events in patients with chronic heart failure. Materials and methods. A systematic literature review was carried out using the PRISMA methodology. PubMed and eLibrary databases were used. Search depth — from 1995 to 2025. For this study, 42 articles were selected for the final analysis. Results. The analyzed signals included electrocardiogram (ECG) (office or 24-hour Holter monitoring) in 28 studies, sphygmogram — in 1 study, acoustic cardiogram, impedance cardiogram, blood pressure (office measurement or 24-hour monitoring) — 4 studies for each biosignal, and pulse rate — 1 study (office measurement); in addition, 95% of the sample were cohort observational studies. The risk of bias in cohort studies was assessed using the Russian version of the Newcastle-Ottawa scale. It was shown that the standard deviation of NN intervals (SDNN, threshold values from 44 to 112 ms) calculated on the basis of 24-hour ECG monitoring data was the most common (in 10 studies) independent predictor of adverse events in a follow-up period of 6 months or more. A randomized controlled trial showed that treatment guided by EMAT% (target value <15%) and S3 score (target value <5) of the acoustic cardiogram was associated with improved outcomes. When combined with clinical status parameters (natriuretic peptide levels, NYHA functional class, peak oxygen consumption), the predictive value of some parameters increases. Information on threshold values of biosignals for scientific and practical application is summarized. Conclusion. It is advisable to simultaneously record multiple biosignals and use a combination of indicators with clinical status parameters to improve the accuracy of predicting adverse events in patients with chronic heart failure.
No takes yet. Share an insight, caveat, or question.
Posnenkova et al. (2026) conducted a systematic review in chronic heart failure (n=42). Non-invasively recorded cardiac biosignals was evaluated on adverse events. Non-invasively recorded cardiac biosignals, most commonly SDNN from 24-hour ECG monitoring, were independent predictors of adverse events in patients with chronic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: